Expert Ratings for Sutro Biopharma
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 6 Wall Street analysts have provided ratings for Sutro Biopharma (NASDAQ:STRO), with 3 giving a bullish and 3 a somewhat bullish rating. The average 12-month price target for STRO is $14.5, with a high of $25.00 and a low of $10.00, representing a 19.44% decrease from the previous target of $18.00. Analysts rate stocks to predict their performance and provide guidance to investors.
November 15, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sutro Biopharma received positive ratings from analysts, with an average price target of $14.5, which is lower than the previous target of $18.00.
While the overall sentiment from analysts is positive, the reduction in the average price target suggests a cautious outlook on the stock's short-term growth potential. This could lead to a neutral impact on the stock price as the positive ratings are balanced by the lowered price target expectations.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100